Sandra L. S.
- Country
- Spain
- Department
- Medical oncology
Research Overview
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Ficlatuzumab and Cetuximab in Recurrent or Metastatic HPV-Negative Head and Neck Squamous Cell Carcinoma
- Phase II Randomized Study of Cisplatin and Radiotherapy Versus Durvalumab and Radiotherapy in Intermediate-Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma
- Evaluation of Cetuximab With or Without Paclitaxel Following Pembrolizumab and Platinum-5FU in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Data & Insights
Has run more than one trial at 11 of 102 partner sites.
Specializations
Breast cancer and endocrine-sensitive disease
The clinical research profile includes hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative breast cancer, with attention to both early-stage and metastatic settings, as well as endocrine-resistant and biomarker-defined disease.
- Early breast cancer
- Metastatic breast cancer
- Triple-negative breast cancer
- HER2-positive breast cancer
Therapeutic interests extend to endocrine-based strategies, targeted combinations, and recurrence-focused treatment approaches in medical oncology.
Hematologic malignancies and bone marrow disorders
Research activity is strongly centered on acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, and a broad spectrum of B-cell and T-cell lymphomas, including relapsed and refractory disease.
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Diffuse large B-cell lymphoma
- Multiple myeloma
Additional interest includes graft-versus-host disease, transplant-associated complications, and anemia linked to marrow failure syndromes.
Thoracic, head and neck, and gastrointestinal cancers
The investigator is involved in trials across non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, and several gastrointestinal malignancies, including gastric, esophageal, colorectal, pancreatic, and biliary tract cancer.
- Non-small cell lung cancer
- Head and neck squamous cell carcinoma
- Gastric and gastroesophageal junction cancer
- Colorectal cancer
Her therapeutic focus also includes biomarker-driven disease such as EGFR, KRAS, ROS1, and HER2-altered tumors.
Genitourinary, gynecologic, and melanoma oncology
Clinical research spans urothelial carcinoma, renal cell carcinoma, and prostate cancer, together with ovarian, endometrial, and cervical cancers, reflecting a strong interest in solid tumors with advanced or recurrent disease.
- Urothelial carcinoma
- Renal cell carcinoma
- Ovarian cancer
- Endometrial cancer
Additional activity includes melanoma, including metastatic and uveal forms, with emphasis on targeted and immune-based treatment options.
Immuno-oncology, cell therapy, and targeted innovation
The investigator’s portfolio includes immune checkpoint inhibition, CAR-T cell therapy, antibody-drug conjugates, and other biomarker-directed approaches across solid and hematologic cancers.
- Immunotherapy
- CAR-T cell therapy
- Antibody-drug conjugates
- Targeted therapy
These interests align with treatment development in advanced malignancies and precision oncology at the Institut Catala d'Oncologia in Barcelona.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.